Alector price target lowered to $8 from $10 at Stifel

Stifel analyst Paul Matteis lowered the firm’s price target on Alector to $8 from $10 and keeps a Hold rating on the shares. In the company’s recent Q2 update, Alector confirmed TREM2 timelines remain on-track and created a new stats plan for its ph3 FTD-GRN program, the analyst tells investors. While there are still many questions, the big upcoming event will be TREM2 Alzheimer’s data in Q4, which remains one of the more promising early mechanisms in AD, Stifel says.